Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Common Stock Repurchased

Cash spent buying back the company's own shares.

Benitec Biopharma Inc.NASDAQ: BNTC

Common Stock Repurchased · Q3 FY2026 · quarter ended Mar 2026

Common stock repurchased outflow grows to $0

Q3 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearJun 2025
$0— YoY
LTMMar 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's LTM Mar 2026 common stock repurchased of $0 is the 4th largest of the 10 companies compared; the peer median is $0.
BNTC Competitors Peer median
Common Stock Repurchased for BNTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XOMAXOMA Royalty Corp.LTM Mar 2026$15.76M +2535.8%—43.5%
PRTCPureTech Health plcFY2025$2.06M -98.1%-57.3%44.2%
OCGNOcugen, Inc.LTM Mar 2026$245K +345.0%—5.5%
BNTCBenitec Biopharma Inc.LTM Mar 2026$0 ———
SLDBSolid Biosciences Inc.LTM Mar 2026$0 +100.0%——
NGNENeurogene Inc.LTM Mar 2026$0 ———
AUTLAutolus Therapeutics plcLTM Mar 2026$0 ——0.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$0 +100.0%—0.0%
QSIQuantum-Si incorporatedLTM Mar 2026$0 ——0.0%
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding BNTC) $0+100.0%-57.3%2.7%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Depreciation & Amortization424K392K381K343K396K
Deferred Income Tax00(714K)00
Stock-Based Compensation634K870K452K830K17.43M
Change in Working Capital8K1.04M714K1.17M(2.73M)
Accounts Receivables28K1K(50K)(176K)197K
Inventory(83K)(1.09M)(1.31M)00
Accounts Payables55K1.09M1.36M0(2.38M)
Other Working Capital8K1.04M714K1.35M(548K)
Other Non-Cash Items(16K)10K717K1K(764K)
Operating Cash Flow(12.83M)(15.9M)(18.01M)(19.4M)(23.59M)
Capital Expenditures(221K)(13K)(1K)(179K)(18K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(221K)(13K)(1K)(179K)(18K)
Debt Repayment00000
Common Stock Issued25.75M017.88M70.88M70.49M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.23M)0(1.87M)(2.85M)0
Financing Cash Flow22.52M016.02M68.03M70.49M
Effect of Forex Changes499K204K412K(8K)49K
Net Change in Cash9.97M(15.71M)(1.59M)48.44M46.93M
Free Cash Flow(13.05M)(15.91M)(18.01M)(19.58M)(23.61M)

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.